Alpha Tau Medical (NASDAQ:DRTS) Announces Earnings Results

Alpha Tau Medical (NASDAQ:DRTS) posted its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13), Zacks reports.

Alpha Tau Medical Price Performance

Shares of NASDAQ DRTS traded up $0.06 during midday trading on Wednesday, hitting $2.66. 18,824 shares of the company’s stock were exchanged, compared to its average volume of 109,398. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $4.39. The firm has a market cap of $186.00 million, a P/E ratio of -6.19 and a beta of 0.87. The stock’s 50 day moving average price is $3.30 and its 200-day moving average price is $2.78.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Friday, November 22nd.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.